In the previous installments of this series (Part One and Part Two), we discussed the development of...

AI is no longer a future concept for life sciences—it is a present-day force reshaping how medicines are developed, manufactured, regulated, and delivered to patients. Yet as AI adoption accelerates, a critical truth has become clear: technology alone is not enough. Sustainable, compliant, and scalable AI transformation depends on people, culture, governance, and organizational readiness.

This post is Part 3 of the Jack Lysfjord Grant blog series. Read Part 1 and Part 2.

The ISPE Mid-Atlantic Science and Technology Showcase (MAST) in Baltimore, Maryland, USA held on 7 May highlighted the strength, technical capability, and collaborative spirit of the life sciences industry. Hosted by the ISPE Chesapeake Bay Area Chapter at M&T Bank Stadium, the show brought together more than 950 registrants from across the pharmaceutical and biotechnology community for a...

The Facility of the Year Awards (FOYA) Category Winners announcement was once again a cornerstone moment of the 2026 ISPE Europe Annual Conference in Copenhagen, Denmark, offering attendees an inside look at the facilities that were shaping the future of...

As a fitting conclusion to the 2026 ISPE Europe Annual Conference, 30 conference attendees took the opportunity to step inside one of the industry’s most advanced biologics manufacturing facilities during a sold out tour of the FUJIFILM Biotechnologies site in Hillerød, Denmark. Held on Thursday, 23 April, the sold-out tour offered attendees an in depth look at how large scale biologics...

ISPE’s upcoming 2026 ISPE AI in Life Sciences Summit – Powered by GAMP^®, taking place 23–24 June in Boston, Massachusetts, will bring together a diverse group of professionals from across the pharmaceutical and tech industry to address the nascent opportunities and challenges for applying artificial intelligence in the...

For those considering joining ISPE, there’s never been a better moment. For a limited time, new and renewing ISPE members can access a free GAMP^® microlearning course—an exclusive offer designed to strengthen foundational knowledge in pharmaceutical manufacturing and regulatory compliance.

The current upstream process, particularly the synthesis step, that has been widely used in the industry, is the Solid Phase Oligonucleotide Synthesis (SPOS). While SPOS remains functional for many companies, it is increasingly perceived as being at the brink of capacity limits, especially in light of the projected increases in demand.

Artificial intelligence is no longer a future concept for the pharmaceutical industry—it’s actively reshaping how quality, manufacturing, and regulatory compliance are managed today. In the latest episode of the

The life sciences industry is undergoing a profound digital transformation, driven by the convergence of artificial intelligence (AI), cloud computing, and advanced analytics. These technologies are reshaping how organizations manage quality across the product lifecycle from development and manufacturing to post-market surveillance.

As artificial intelligence (AI) continues to accelerate across the life sciences industry, leaders face a critical question: how do we adopt AI at scale without compromising patient safety, data integrity, or regulatory compliance? The 2026 ISPE AI in Life...

The rational and regulated application of LLMs in GMP biotech IT compliance work can effectively eliminate the risks of information disclosure.